Xenia Bacinschi1, Anca Florina Zgura1, Adriana Mercan-Stanciu2, Mugur Grasu3, Vlad Herlea4, Letitia Toma2, Mihai Dodot2, Alexandru Martiniuc5, Rodica Anghel1, Bogdan Haineala2. 1. Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 2. Department of Internal Medicine II, Fundeni Clinical Institute,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 3. Department of Interventional Radiology, Fundeni Clinical Institute,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 4. Department of Pathology, Fundeni Clinical Institute, Bucharest, Romania. 5. Department of General Surgery, Fundeni Clinical Institute,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Abstract
Background/Aim: Fibrolamellar carcinoma is a rare primary hepatic malignancy that has recently been recognized as a distinct clinical entity, highly different from the well-known hepatocellular carcinoma. This report describes the clinical and paraclinical aspects of the fibrolamellar carcinoma, emphasizing its particularities. Case Report: A 30-year-old patient presented to the hospital with nonspecific symptoms and weight loss, with imaging findings showing abdominal and mediastinal masses. Multiple biopsies were performed, leading to a diagnosis of metastatic fibrolamellar carcinoma. Given the extent of the disease, systemic drug treatment was administered, although prognosis was poor with tumor growth, resulting in biliary duct invasion. Conclusion: Fibrolamellar carcinoma is a rare type of malignancy, with a difficult differential diagnosis in which imaging techniques are important but for which biopsy remains the gold standard. The prognosis depends on tumor extent and may include surgical methods or chemotherapy. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Fibrolamellar carcinoma is a rare primary hepatic malignancy that has recently been recognized as a distinct clinical entity, highly different from the well-known hepatocellular carcinoma. This report describes the clinical and paraclinical aspects of the fibrolamellar carcinoma, emphasizing its particularities. Case Report: A 30-year-old patient presented to the hospital with nonspecific symptoms and weight loss, with imaging findings showing abdominal and mediastinal masses. Multiple biopsies were performed, leading to a diagnosis of metastatic fibrolamellar carcinoma. Given the extent of the disease, systemic drug treatment was administered, although prognosis was poor with tumor growth, resulting in biliary duct invasion. Conclusion: Fibrolamellar carcinoma is a rare type of malignancy, with a difficult differential diagnosis in which imaging techniques are important but for which biopsy remains the gold standard. The prognosis depends on tumor extent and may include surgical methods or chemotherapy. Copyright 2021, International Institute of Anticancer Research.
Authors: Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan Journal: Oncology Date: 2013-09-19 Impact factor: 2.935
Authors: Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon Journal: Science Date: 2014-02-28 Impact factor: 47.728
Authors: V B Weeda; M Murawski; A J McCabe; R Maibach; L Brugières; D Roebuck; M Fabre; A Zimmermann; J B Otte; M Sullivan; G Perilongo; M Childs; P Brock; J Zsíros; J Plaschkes; P Czauderna; D C Aronson Journal: Eur J Cancer Date: 2013-05-15 Impact factor: 9.162